Efewongbe Oleghe
Internal Medicine · Cleveland, OHNPI 1003224577
Payments from drug & device makers
Across 207 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$815
- Lilly USA, LLC$268
- Astellas Pharma US Inc$253
- Novo Nordisk$173
- Amgen$164
- Smith+Nephew$154
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,26097%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $815 |
| Lilly USA, LLC | 16 | $268 |
| Astellas Pharma US Inc | 10 | $253 |
| Novo Nordisk | 11 | $173 |
| Amgen | 10 | $164 |
| Smith+Nephew | 18 | $154 |
| Otsuka America Pharmaceutical, Inc. | 8 | $139 |
| GSK | 8 | $119 |
| Corcept Therapeutics | 6 | $115 |
| Johnson & Johnson | 6 | $100 |
| Integra Lifesciences Corporation | 1 | $83 |
| Amarin Pharma, Inc. | 5 | $81 |
| AstraZeneca | 5 | $77 |
| Exact Sciences | 4 | $74 |
| Boehringer Ingelheim | 4 | $72 |
| Merck | 4 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Pfizer | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 1 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Kerecis Limited | 1 | $39 |
| Bayer | 2 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Lundbeck LLC | 2 | $30 |
| Genentech USA, Inc. | 1 | $23 |
| Bioventus LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Radius Health, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Soleno Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Medtronic | 1 | $12 |
How this compares
$3,360 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 453 | $171,807 |
| JanuviaSitagliptin Phosphate | 100 | $65,524 |
| NuplazidPimavanserin Tartrate | 26 | $63,555 |
| TrulicityDulaglutide | 54 | $53,833 |
| JardianceEmpagliflozin | 62 | $49,369 |
| ProliaDenosumab | 25 | $43,530 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $29,687 |
| OzempicSemaglutide | 30 | $28,757 |
| FarxigaDapagliflozin Propanediol | 52 | $27,955 |
| MyrbetriqMirabegron | 53 | $26,318 |
| GemtesaVibegron | 41 | $23,801 |
| XareltoRivaroxaban | 31 | $22,152 |
| RexultiBrexpiprazole | 27 | $19,698 |
| EntrestoSacubitril/Valsartan | 47 | $14,121 |
| LinzessLinaclotide | 22 | $13,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $171,807453 claims |
| MerckJanuvia | $57 | $65,524100 claims |
| Boehringer IngelheimJardiance, Tradjenta | $72 | $60,61277 claims |
| Lilly USA, LLCTrulicity | $268 | $53,83354 claims |
| AmgenProlia | $164 | $43,53025 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $77 | $43,30696 claims |
| GSKTrelegy Ellipta | $119 | $29,68743 claims |
| Novo NordiskOzempic | $173 | $28,75730 claims |
| Astellas Pharma US IncMyrbetriq | $253 | $26,31853 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $35 | $23,80141 claims |
| Johnson & JohnsonXarelto | $100 | $22,15231 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $139 | $19,69827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cleveland
- Vadim KoshkinCleveland$6.1M
- Emily LittlejohnCleveland$885K
- Marina MagreyCleveland$856K
- Pushkar KanadeCleveland$753K
- Cyrus HarrisCleveland$726K
- Ila TamaskarCleveland$721K
- Amar KrishnaswamyCleveland$552K
- Albree Tower-RaderCleveland$522K
- Adriano TonelliCleveland$464K
- Mahboob RahmanCleveland$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.